{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "4154319",
  "DateCompleted": {
    "Year": "1975",
    "Month": "02",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "10",
    "Day": "30"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0020-8272",
      "JournalIssue": {
        "Volume": "9",
        "Issue": "3",
        "PubDate": {
          "Year": "1974"
        }
      },
      "Title": "International pharmacopsychiatry",
      "ISOAbbreviation": "Int Pharmacopsychiatry"
    },
    "ArticleTitle": "The peripheral and central role of the catecholamines in the mechanisms of anxiety.",
    "Pagination": {
      "StartPage": "125",
      "EndPage": "137",
      "MedlinePgn": "125-37"
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Lader",
        "ForeName": "M",
        "Initials": "M"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Int Pharmacopsychiatry",
    "NlmUniqueID": "0135645",
    "ISSNLinking": "0020-8272"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Adrenergic beta-Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Anxiety Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Catecholamines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Sympatholytics"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Sympathomimetics"
    },
    {
      "RegistryNumber": "12794-10-4",
      "NameOfSubstance": "Benzodiazepines"
    },
    {
      "RegistryNumber": "9Y8NXQ24VQ",
      "NameOfSubstance": "Propranolol"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Adrenergic beta-Antagonists"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Anxiety Agents"
    },
    {
      "QualifierName": [
        "chemically induced",
        "complications",
        "drug therapy",
        "metabolism",
        "physiopathology"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "physiopathology"
      ],
      "DescriptorName": "Anxiety Disorders"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Arousal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Benzodiazepines"
    },
    {
      "QualifierName": [
        "physiopathology"
      ],
      "DescriptorName": "Brain"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Brain Chemistry"
    },
    {
      "QualifierName": [
        "metabolism",
        "physiology"
      ],
      "DescriptorName": "Catecholamines"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Cerebral Ventricles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cognition"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Models, Biological"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Propranolol"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Stress, Physiological"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Sympatholytics"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Sympathomimetics"
    }
  ]
}